Daewoong Pharmaceutical acquires preferential sale right in KRW 150 billion hepatitis B generic market
Daewoong Pharmaceutical will enter the market of ‘tenofovir,’ a hepatitis B treatment, worth of approximately KRW 150 billion.
Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced on the 14th that ‘Virihepa,’ its hepatitis B treatment containing the ‘tenofovir’ substance, acquired the preferenti...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
